Terapias target más quimioterapia comparado con quimioterapia en cáncer de mama triple negativo EC IV o recurrente. Revisión sistemática y metaanálisis

Jorge Aliaga-Caján, José Caballero-Alvarado, Raúl Sandoval-Ato, Joshuan Barboza-Meca, Víctor Serna-Alarcón

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

Resumen

Background: Breast cancer is the most common malignancy in women worldwide. Patients with triple negative breast cancer represent a subgroup with unfavorable prognosis especially in advanced stages of the disease. Several first-line therapeutic agents have been described. Objective: To perform a systematic review and meta-analysis to compare target therapies plus chemotherapy with chemotherapy in the treatment of patients with triple negative breast cancer Stage IV or recurrent. Material and Methods: A systematic search identified randomized clinical studies for the treatment of triple negative breast cancer in Stage IV or recurrent. The outcomes of interest were overall survival (OS) and progression-free survival (PFS). Data from each clinical study were recorded for the outcomes and the relative risk was estimated. Results: 10 studies were included and participants ranged from 53 to 902 per study. Regarding overall survival, we observed that target therapy plus chemotherapy in patients with triple-negative Stage IV or recurrent breast cancer was associated with a 15% decrease in the risk of mortality with a RR (95% CI): 0.85 (0.70 to 1.03). In relation to the level of progression-free risk, we observed that the intervention showed a 16% decrease in the risk of progression with a RR (95% CI): 0.84 (0.74 to 0.95). Progression-free survival in patients with the intervention ranged from 2.8 to 9.7 months, while in conventional therapy it ranged from 1.5 to 6.2 months. Conclusion: Patients with Stage IV or recurrent triple negative breast cancer who received target therapy plus chemotherapy showed a trend towards decreased risk of disease progression (PFS) and mortality (OS), however, more clinical studies are required to validate its significance.

Título traducido de la contribuciónTarget therapies plus chemotherapy compared to chemotherapy in Stage IV or recurrent triple negative breast cancer. A Systematic Review and Meta-analysis
Idioma originalEspañol
Páginas (desde-hasta)163-172
Número de páginas10
PublicaciónRevista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
Volumen14
N.º2
DOI
EstadoPublicada - 30 jun 2021
Publicado de forma externa

Palabras clave

  • Chemotherapy
  • Metastatic breast cancer: Target therapies
  • Triple-negative breast cancer

Huella

Profundice en los temas de investigación de 'Terapias target más quimioterapia comparado con quimioterapia en cáncer de mama triple negativo EC IV o recurrente. Revisión sistemática y metaanálisis'. En conjunto forman una huella única.

Citar esto